newsfilter
← Earnings
Earnings Releases·

Alkermes — Third Quarter 2026 Earnings Summary

  • Total revenues reached $480.1 million for the quarter (up from $394.2 million in 2025) and $1.37 billion for the nine-month period (up from $1.09 billion), while GAAP net income declined to $16.3 million from $82.8 million in the prior year quarter.
  • Adjusted EBITDA remained stable at $120.1 million for the quarter (vs. $121.5 million in 2025) and rose to $339.5 million for the nine months (vs. $293.7 million), driven by proprietary product revenue growth to $417.3 million.
  • The company reiterated its full-year 2026 financial guidance and highlighted the advancement of its orexin portfolio, including proof-of-concept data in ADHD and the initiation of a Phase 2 study in major depressive disorder.
  • Significant transaction-related costs from the Avadel Pharmaceuticals acquisition totaled $29.8 million for the quarter, contributing to elevated R&D and SG&A expenses compared to the prior year period.
Company
ALKERMES PLC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic